KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation: 2010-2018

Historic Accumulated Depreciation for Arbutus Biopharma (ABUS) over the last 8 years, with Dec 2018 value amounting to $6.9 million.

  • Arbutus Biopharma's Accumulated Depreciation fell 45.58% to $6.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.9 million, marking a year-over-year decrease of 45.58%. This contributed to the annual value of $6.9 million for FY2018, which is 45.58% down from last year.
  • Per Arbutus Biopharma's latest filing, its Accumulated Depreciation stood at $6.9 million for Q4 2018, which was up 7.88% from $6.4 million recorded in Q3 2018.
  • Arbutus Biopharma's Accumulated Depreciation's 5-year high stood at $13.3 million during Q1 2018, with a 5-year trough of $5.9 million in Q2 2018.
  • Its 3-year average for Accumulated Depreciation is $10.1 million, with a median of $10.6 million in 2016.
  • In the last 5 years, Arbutus Biopharma's Accumulated Depreciation skyrocketed by 200.65% in 2014 and then crashed by 48.92% in 2018.
  • Over the past 5 years, Arbutus Biopharma's Accumulated Depreciation (Quarterly) stood at $11.2 million in 2014, then decreased by 13.13% to $9.7 million in 2015, then climbed by 10.37% to $10.7 million in 2016, then climbed by 18.00% to $12.7 million in 2017, then tumbled by 45.58% to $6.9 million in 2018.
  • Its Accumulated Depreciation stands at $6.9 million for Q4 2018, versus $6.4 million for Q3 2018 and $5.9 million for Q2 2018.